1D09C3 

1D09C3 is a fully human anti-HLA-DR monoclonal antibody. 1D09C3 induces apoptosis and cell death involving a cascade of events, including ROS generation, JNK activation, mitochondrial membrane depolarization, and AIF release from mitochondria. 1D09C3 shows potent anti-tumor activity and increases overall survival and median survival in JVM-2 cells and GRANTA-519 cells xenograft mice models. 1D09C3 can be used for the researches of cancer, such as chronic lymphocytic leukemia (CLL)^[1][2][3].

HLA-DR β

1D09C3 (2.5 µg/ mL, 24 h) significantly reduces cell countings and cell survival in HLA-DR⁺, but not HLA-DR^- cell lines^[1][2].

1D09C3 (0.1-10 µg/ mL, 4-24 h) induces a potent time- and dose-dependent death of JVM-2 and GRANTA-519 cells^[1].

1D09C3 (10 µg/ mL, 4-24 h) induces cell apoptosis through a caspase-independent pathway in JVM-2 and GRANTA-519 cells^[1].

1D09C3 (10 µg/ mL, 5-240 min) induces mitochondrial depolarization and generation of ROS in JVM-2 and GRANTA-519 cells^[1].

1D09C3 (10 µg/ mL, 0.5-4 h) induces cell death involving activation of the JNK^[1].

1D09C3 (2.5 µg/ mL, 4 h) induces cell death B-CLL cell death^[1][3].

1D09C3 (10 µg/ mL, 48 h) reduces cell counts by 20% for activated T cells and by 50% for resting and activated B cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1D09C3 (0.01-6 mg/mouse, i.v.) significantly increases overall survival and median survival in JVM-2 cells and GRANTA-519 cells xenograft mice models ^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

791073-97-7

N/A

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Carlo-Stella C, et al. The anti-human leukocyte antigen-DR monoclonal antibody 1D09C3 activates the mitochondrial cell death pathway and exerts a potent antitumor activity in lymphoma-bearing nonobese diabetic/severe combined immunodeficient mice. Cancer Res. 2006 Feb 1;66(3):1799-808.  [Content Brief]

  [2]. Carlo-Stella C, et al. IFN-gamma enhances the antimyeloma activity of the fully human anti-human leukocyte antigen-DR monoclonal antibody 1D09C3. Cancer Res. 2007 Apr 1;67(7):3269-75.  [Content Brief]

  [3]. Nagy ZA, et al. Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells. Nat Med. 2002 Aug;8(8):801-7.  [Content Brief]